Your browser doesn't support javascript.
Using host receptor as a decoy to treat COVID-19: a solution for immune escape?
Huang, Kuo-Yen; Lin, Ming-Shiu; Yang, Pan-Chyr.
  • Huang KY; YongLin Institute of Health, National Taiwan University, Taipei, Taiwan.
  • Lin MS; Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Yang PC; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
EMBO Mol Med ; 14(11): e16818, 2022 Nov 08.
Article in English | MEDLINE | ID: covidwho-2081082
ABSTRACT
There is an unmet clinical need to end the COVID-19 pandemic. In the past 2 years, the SARS-CoV-2 continued to evolve and poses a critical challenge to the efficacy of the vaccine and neutralizing antibody therapies. The fifth wave of the pandemic is driven by the Omicron variants, due to their ability to evade prior immunity and their resistance to therapeutic antibodies. The report by Zhang et al in the current issue of EMBO Molecular Medicine shows that the engineered decoy ACE2 can reduce lung injury and improve survival in K18-hACE2 transgenic mice inoculated with a lethal dose of the SARS-CoV-2 and potentially targets the Omicron variant.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: EMBO Mol Med Journal subject: Molecular Biology Year: 2022 Document Type: Article Affiliation country: Emmm.202216818

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: EMBO Mol Med Journal subject: Molecular Biology Year: 2022 Document Type: Article Affiliation country: Emmm.202216818